*July 2021* Note: Although the use of immunotherapy can be questionable in EGFR+ lung cancer, resistance to immunotherapy might be
About email@example.comThis author has not yet filled in any details.
So far firstname.lastname@example.org has created 176 blog entries.
*May 2021* Note: Is further evaluation of the combination warranted for patients with locally advanced or metastatic T790M-negative, EGFR-positive NSCLC? The
Osimertinib Combinations as Second-Line Treatment in Non-Small Cell Lung Cancer: The Jury’s Still Outlaurabbook@gmail.com2021-09-07T17:39:36-07:00
*July 2021* Note Should a VEGF inhibitor (bevacizumab/Avastin) be combined with osimertinib or not? The role of osimertinib combinations as second-line treatment
*July 2021* Patritumab deruxtecan (HER3-DXd), an antibody drug conjugate consisting of a fully human monoclonal antibody to HER3 attached to
Amivantamab/Lazertinib Combination May Overcome Osimertinib Resistance in Patients With EGFR-Positive NSCLClaurabbook@gmail.com2021-09-07T17:15:42-07:00
*July 2021* Combination targeting of epidermal growth factor receptor (EGFR) with amivantamab/lazertinib achieved durable responses in more than one-third of chemotherapy-naive
*July 2021* As research efforts prevail with encouraging therapies designed to overcome resistance to EGFR-directed therapies for patients with advanced
*July 2021* Osimertinib (Tagrisso) has emerged as the standard of care for patients with EGFR-mutated non–small cell lung cancer (NSCLC),
*July 2021* Strategies focused on improving the efficacy of the EGFR tyrosine kinase inhibitor (TKI) osimertinib (Tagrisso) in the first
*June 2021* Data from a landmark research study shows that the biology behind “young” lung cancer – lung cancer diagnosed
*August 2021* The CHRYSALIS Study is for adults with previously treated advanced non-small-cell lung cancer (NSCLC). The study is broken